Medipharm Labs In December 2018 Ships Over CAD$10m Of Cannabis Oil

  • Jan 17, 2019 AEDT
  • Team Kalkine
Medipharm Labs In December 2018 Ships Over CAD$10m Of Cannabis Oil

The company is pleased to attach a copy of a news release by MediPharm Labs Inc announcing that it had shipped over CAD$10 million of cannabis oil in December 2018. There is a 4.3% shareholding and 2.9 million warrants in MediPharm Labs and MMJ has approximately about 4.4 million shares. The investment signifies approx. 17% of the market value of MMJ's total investment portfolio.

Focused on downstream secondary extraction methodology, cannabinoid isolation, and purification, distillation, Medipharm labs corp., the leader in specialized fully under the Cannabis Act for research-driven cannabis extraction, is pleased to announce it has three cannabis oil sales agreements.

In December 2018 aggressively valued at over $10 million the first large shipments of cannabis oil supply left by the company’s dock. Medipharm labs have emerged as the class leader in the category of extraction, as a pioneer in the cannabis industry which is highlighted by the first month of sales agreements of high-quality concentrate.

The company continues to build momentum as it is increasingly being recognized for toll processing particularly among mid-to-large-sized vertically integrated licensed producers and as the supplier of choice for high quality purified cannabis oil and the company sees a clear path for sustainable and continued growth in 2019 and beyond.

The company’s strong momentum is continuing in 2019 with accomplishments like white label program which is processed and sold large quantities of dried cannabis to ensure supply of oil for all customers. The company also with 6 LPs under Cannabis Concentrates Program executed multiple long-term tolling arrangements. The initial capacity of drying capacity was increased to 150,000 kg which increased by 50% as approved by health Canada Dec 24, 2018.

Through the multitude of substantial contracts, the company is looking forward to accelerating growth and strong pipelines of opportunities to be enhanced in the near term. To extract and import/export medical cannabis product the company has completed the application process with the federal office of Drug Control.

MMJ traded at a market price of $0.275 which is up by 5.769% or $0.015. The daily number of shares traded were at 455,307. The company has performed negative -48.51% in the past year but has recovered to 30.00% in the past month. The market cap as at January 17, 2019, is $59.84 million. The company has an attractive P/E of 1.980 and EPS of 0.131 AUD.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK